1,3-Dihydro-1-oxo-2H-isoindole-2-acetaldehyde | 1163250-37-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异吲哚及其衍生物
• 英文名称: 1,3-Dihydro-1-oxo-2H-isoindole-2-acetaldehyde
• 英文别名: 2-(3-oxo-1H-isoindol-2-yl)acetaldehyde
• CAS: 1163250-37-0
• 化学式: C₁₀H₉NO₂
• 分子量: 175.187
• InChiKey: JGBOZLYDDQXFMJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  37.4
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  2-(2-hydroxyethyl)-1-isoindolinone 在 草酰氯 、 二甲基亚砜 、 三乙胺 作用下， 以 二氯甲烷 为溶剂， 以12%的产率得到1,3-Dihydro-1-oxo-2H-isoindole-2-acetaldehyde
  参考文献：
  名称：

  组成多样的N-氨基烷基化的异吲哚啉酮的互补合成方法：在Falipamil和5-HT1A受体配体类似物的合成中的应用

  摘要：

  已经开发了用于加工尾部具有结构上不同的氨基烷基化链的聚和不同取代的异吲哚满酮的不同合成方法。关键步骤基于带有羟烷基附件的异吲哚啉酮模板的初步组装。末端羟基官能团的后续操作提供了目标化合物，这些方法的合成效用已被缓动剂falipamil和5-HT 1A受体配体类似物的合成所强调。 碳负离子-金属化-内酰胺-闭环-开环

  DOI：

  10.1055/s-0028-1088048

文献信息

• [EN] DUAL NAV1.2/5HT2A INHIBITORS FOR TREATING CNS DISORDERS<br/>[FR] INHIBITEURS DOUBLES DE NAV1.2/5HT2A POUR TRAITER DES TROUBLES DU SNC
  申请人：SUNOVION PHARMACEUTICALS INC

  公开号：WO2018026371A1

  公开（公告）日：2018-02-08

  Compounds of formula I: I are disclosed, as are pharmaceutical compositions containing such compounds. Methods of treating neurological or psychiatric disorders in a patient in need are also disclosed. Such disorders include depression, bipolar disorder, pain, schizophrenia, obsessive compulsive disorder, addiction, social disorder, attention deficit hyperactivity disorder, an anxiety disorder, autism, a cognitive impairment, or a neuropsychiatric symptom such as apathy, depression, anxiety, psychosis, aggression, agitation, impulse control disorders, and sleep disorders in neurological disorders such as Alzheimer's and Parkinson's diseases.

  公开了化学式I的化合物，以及含有这些化合物的药物组合物。还公开了治疗患有神经系统或精神障碍的患者的方法。这些障碍包括抑郁症、躁郁症、疼痛、精神分裂症、强迫症、成瘾、社交障碍、注意力缺陷多动障碍、焦虑障碍、自闭症、认知障碍，或神经精神症状，如冷漠、抑郁、焦虑、精神病、攻击性、激动、冲动控制障碍，以及在神经系统疾病如阿尔茨海默病和帕金森病中的睡眠障碍。
• CRYSTALLINE OF CAMPHORSULFONIC ACID SALT OF RUCAPARIB AND METHOD OF PREPARING OF TRICYCLIC COMPOUNDS, RUCAPARIB AND CRYSTALLINE OF CAMPHORSULFONIC ACID SALT OF RUCAPARIB
  申请人：Formosa Laboratories, Inc.

  公开号：US20200165261A1

  公开（公告）日：2020-05-28

  A method of preparing a tricyclic compound of formula (I), comprising the step of converting a compound of formula (II) into a compound of formula (III); and hydrogenating the compound of formula (III) in the presence of hydrogenation catalyst and hydrogen to form the tricyclic compound of formula (I); wherein R 1 is H or a C 1-3 alkyl group; and R 2 is H, a halogen element or a C 1-3 alkyl group.

  一种制备化合物(I)的三环化合物的方法，包括将化合物(II)转化为化合物(III)的步骤；并在氢化催化剂和氢气的存在下氢化化合物(III)以形成化合物(I)的三环化合物；其中R1是H或C1-3烷基基团；R2是H、卤素元素或C1-3烷基基团。
• Crystalline of camphorsulfonic acid salt of rucaparib and method of preparing of tricyclic compounds, rucaparib and crystalline of camphorsulfonic acid salt of rucaparib
  申请人：Formosa Laboratories, Inc.

  公开号：US11021483B2

  公开（公告）日：2021-06-01

  A method of preparing a tricyclic compound of formula (I), comprising the step of converting a compound of formula (II) into a compound of formula (III); and hydrogenating the compound of formula (III) in the presence of hydrogenation catalyst and hydrogen to form the tricyclic compound of formula (I); wherein R1 is H or a C1-3 alkyl group; and R2 is H, a halogen element or a C1-3 alkyl group.

  一种制备式(I)三环化合物的方法，包括以下步骤：将式(II)化合物转化为式(III)化合物；在氢化催化剂和氢气存在下氢化式(III)化合物，形成式(I)三环化合物；其中 R1 为 H 或 C1-3 烷基；R2 为 H、卤素或 C1-3 烷基。
• Dual NAV1.2/5HT2a inhibitors for treating CNS disorders
  申请人：Sunovion Pharmaceuticals Inc.

  公开号：US11186564B2

  公开（公告）日：2021-11-30

  Compounds of formula I: are disclosed, as are pharmaceutical compositions containing such compounds. Methods of treating neurological or psychiatric disorders in a patient in need are also disclosed. Such disorders include depression, bipolar disorder, pain, schizophrenia, obsessive compulsive disorder, addiction, social disorder, attention deficit hyperactivity disorder, an anxiety disorder, autism, a cognitive impairment, or a neuropsychiatric symptom such as apathy, depression, anxiety, psychosis, aggression, agitation, impulse control disorders, and sleep disorders in neurological disorders such as Alzheimer's and Parkinson's diseases.

  式 I 的化合物： 以及含有此类化合物的药物组合物。还公开了治疗有需要的患者的神经或精神障碍的方法。此类疾病包括抑郁症、双相情感障碍、疼痛、精神分裂症、强迫症、成瘾症、社交障碍、注意力缺陷多动障碍、焦虑症、自闭症、认知障碍或神经精神症状，如冷漠、抑郁、焦虑、精神病、攻击性、激动、冲动控制障碍，以及神经系统疾病如阿尔茨海默病和帕金森病的睡眠障碍。
• Complementary Synthetic Approaches to Constitutionally Diverse N-Aminoalkylated Isoindolinones: Application to the Synthesis of Falipamil and 5-HT1A Receptor Ligand Analogues
  作者：Axel Couture、Magali Lorion、Eric Deniau、Pierre Grandclaudon

  DOI：10.1055/s-0028-1088048

  日期：2009.6

  Different synthetic approaches for the elaboration of poly and diversely substituted isoindolinones tailed with constitutionally diverse aminoalkylated chains have been developed. The key step is based upon the preliminary assembly of the isoindoli­none template equipped with hydroxyalkyl appendages. Subsequent manipulation of the terminal hydroxy functionality afforded the targeted compounds and the

  已经开发了用于加工尾部具有结构上不同的氨基烷基化链的聚和不同取代的异吲哚满酮的不同合成方法。关键步骤基于带有羟烷基附件的异吲哚啉酮模板的初步组装。末端羟基官能团的后续操作提供了目标化合物，这些方法的合成效用已被缓动剂falipamil和5-HT 1A受体配体类似物的合成所强调。 碳负离子-金属化-内酰胺-闭环-开环